Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
64 studies found for:    breast,cancer,PARP
Show Display Options
Rank Status Study
1 Active, not recruiting AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Conditions: Breast Cancer;   Ovarian Cancer
Intervention: Drug: AZ2281 + Carboplatin
2 Active, not recruiting PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Rucaparib
3 Active, not recruiting
Has Results
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: KU-0059436 (AZD2281) (PARP inhibitor)
4 Recruiting Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Interventions: Drug: BKM120 and Olaparib;   Drug: BYL719 and Olaparib
5 Completed A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: gemcitabine plus carboplatin plus BSI-201
6 Active, not recruiting Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
Condition: Breast Cancer Female
Interventions: Drug: paclitaxel;   Drug: Iniparib (SAR2405550 -BSI-201)
7 Recruiting Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer
Conditions: BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Atezolizumab;   Other: Laboratory Biomarker Analysis;   Drug: Veliparib
8 Completed A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer;   Progesterone Receptor Negative (PR-Negative) Breast Cancer;   Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer;   Brain Metastases
Intervention: Drug: INIPARIB + irinotecan
9 Active, not recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Drug: Veliparib
10 Active, not recruiting
Has Results
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Conditions: Ovarian Carcinoma;   Breast Cancer
Intervention: Drug: AZD2281
11 Completed Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338);   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
12 Recruiting A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Placebo
13 Not yet recruiting Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Solid Neoplasm;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Onalespib;   Other: Pharmacological Study
14 Recruiting A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Conditions: Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Interventions: Drug: talazoparib;   Drug: Physician's-Choice
15 Recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer
Conditions: Breast Cancer;   Malignant Female Reproductive System Neoplasm
Interventions: Drug: Olaparib;   Drug: AZD2014;   Drug: AZD5363
16 Withdrawn Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Conditions: Adult Solid Neoplasm;   Estrogen Receptor Negative;   Fallopian Tube Serous Neoplasm;   HER2/Neu Negative;   Ovarian Serous Adenocarcinoma;   Ovarian Serous Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
17 Active, not recruiting ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Conditions: Breast Cancer;   Metastatic Breast Cancer;   BRCA1 Gene Mutation;   brca2 Gene Mutation
Interventions: Drug: ABT-888;   Drug: temozolomide
18 Completed Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Condition: Breast Cancer, Metastatic
Interventions: Drug: Iniparib;   Drug: Gemcitabine;   Drug: Carboplatin
19 Active, not recruiting Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Conditions: Advanced Ovarian Cancer;   Primary Peritoneal Cancer;   Advanced Breast Cancer;   Advanced Solid Tumors
Intervention: Drug: BMN 673
20 Recruiting Olaparib and Radiotherapy in Inoperable Breast Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Inflammatory Breast Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Interventions: Radiation: radiotherapy;   Drug: olaparib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.